Methamphetamine effects in zebrafish (Danio rerio) depend on behavioral endpoint, dose and test session duration
Pharmacology Biochemistry and Behavior · 2024
DOI: 10.1016/j.pbb.2024.173777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2024. Verfasst von Susan Schenk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Zoology, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Zebrafish, Methamphetamine, Dose-Response Relationship, Drug, Behavior, Animal. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maurice and Phyllis Paykel Trust.
Abstract (Originalsprache)
Research using zebrafish (Danio rerio) has begun to provide novel information in many fields, including the behavioral pharmacology of drug use and misuse. There have been limited studies on the effects of methamphetamine in adult zebrafish and the parameters of exposure (dose, test session length) have not been well-documented. Behavior following drug exposure is generally measured during relatively short sessions (6-10 min is common) in a novel tank environment. Many procedural variables (isolation, netting, novel tank) elicit anxiety-like behavior that is most apparent during the initial portion of a test session. This anxiety-like behavior might mask the initial effects of methamphetamine. During longer test sessions, these anxiety-like responses would be expected to habituate and drug effects should become more apparent. To test this idea, we measured several locomotor activity responses for 50-min following a range of methamphetamine doses (0.1-3.0 mg/L via immersion in methamphetamine solution). Methamphetamine failed to alter swimming velocity, distance travelled, or freezing time. In contrast, methamphetamine produced a dose-dependent decrease in time spent in the bottom of the tank, an increase in the number of visits to the top of the tank, and an increase in the number of transitions along the sides of the tank. The effects of methamphetamine were apparent 10-20 min following exposure and generally persisted throughout the session. These findings indicate that longer test sessions are required to measure methamphetamine-induced changes in behavior in zebrafish, as has been shown in other laboratory animals. The results also suggest that anxiety-like responses associated with various procedural aspects (netting, isolation, novel test apparatus) likely interfere with the ability to observe many behavioral effects of methamphetamine in zebrafish. Based on the current results, habituation to testing procedures to reduce anxiety-like behaviors is recommended in determining the effects of methamphetamine in zebrafish.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Zoology, University of Otago, Dunedin, New Zealand.
- Department of Pathology, University of Otago, Dunedin, New Zealand.
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA.
- Department of Zoology, University of Otago, Dunedin, New Zealand. Electronic address: sheri.johnson@otago.ac.nz.
Förderung
- Maurice and Phyllis Paykel Trust
Zitieren
APA
Schenk, S., Horsfield, J. A., Dwoskin, L., & Johnson, S. L. (2024). Methamphetamine effects in zebrafish (Danio rerio) depend on behavioral endpoint, dose and test session duration. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2024.173777
Vancouver
Schenk S, Horsfield JA, Dwoskin L, Johnson SL. Methamphetamine effects in zebrafish (Danio rerio) depend on behavioral endpoint, dose and test session duration. Pharmacology Biochemistry and Behavior. 2024. doi:10.1016/j.pbb.2024.173777
BibTeX
@article{Schenk2024,
author = {Schenk, Susan and Horsfield, Julia A and Dwoskin, Linda and Johnson, Sheri L},
title = {Methamphetamine effects in zebrafish (Danio rerio) depend on behavioral endpoint, dose and test session duration},
journal = {Pharmacology Biochemistry and Behavior},
year = {2024},
doi = {10.1016/j.pbb.2024.173777}
}
EUVIMED